⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2417878 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL8140710 | 0.87 | — | — | |
| SCHEMBL206768 | 0.84 | CHRM2 (0.36) | — | |
| SCHEMBL16941990 | 0.78 | — | — | |
| SCHEMBL205952 | 0.77 | CHRM2 (0.42) | — | |
| Hydrochloric Acid SCHEMBL6990830 | 0.75 | CHRM2 (0.41) | — | |
| SCHEMBL592855 | 0.74 | FFAR3 (0.35) | — | |
| SCHEMBL9444180 | 0.72 | CHRM2 (0.31) | — | |
| SCHEMBL205678 | 0.70 | CHRM2 (0.38) | — | |
| Hydrochloric Acid SCHEMBL14742183 | 0.70 | PKM (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720035-A1 | LIPID COMPOUNDS, COMPOSITIONS, AND USES THEREOF | LIBERATE BIO, INC. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4584259-A1 | CK1ALPHA AND DUAL CK1ALPHA / GSPT1 DEGRADING COMPOUNDS | Innovo Therapeutics, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024249525-A1 | LIPID COMPOUNDS, COMPOSITIONS, AND USES THEREOF | LIBERATE BIO, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20240158370-A1 | CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS | INNOVO THERAPEUTICS, INC. | 2024-05-16 | — | — | US | disclosed |
| WO-2024054832-A1 | CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS | INNOVO THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| US-20230036854-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | THE UNIVERSITY OF SHEFFIELD (GB) | 2023-02-02 | — | — | US | disclosed |
| CN-114007695-A | As AM2Heterocyclic spiro-compounds as receptor inhibitors | 谢菲尔德大学 | 2022-02-01 | — | — | CN | disclosed |
| EP-3880308-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | The University Of Sheffield (GB) | 2021-09-22 | — | — | EP | disclosed |
| WO-2020099885-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | THE UNIVERSITY OF SHEFFIELD (GB) | 2020-05-22 | — | — | WO | disclosed |
| US-9238657-B2 | Cephalosporin having catechol group | SHIONOGI & CO., LTD. (JP) | 2016-01-19 | — | — | US | disclosed |
| WO-2009099736-A2 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090197863-A1 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| EP-1028961-B3 | PLEUROMUTILIN DERIVATIVES AS ANTIMICROBIALS | SMITHKLINE BEECHAM PLC (GB) | 2008-12-03 | — | — | EP | disclosed |
| EP-1930330-A1 | Pleuromutilin derivatives as antimicrobials | SMITHKLINE BEECHAM PLC (GB) | 2008-06-11 | — | — | EP | disclosed |
| US-RE39128-E1 | ANTIBACTERIA DRUG; RESPIRATORY SYSTEM DISORDERS; OTITIS | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-06-13 | — | — | US | disclosed |
| EP-1028961-B1 | PLEUROMUTILIN DERIVATIVES AS ANTIMICROBIALS | SMITHKLINE BEECHAM PLC (GB) | 2004-09-29 | — | — | EP | disclosed |
| EP-1452534-A1 | PLEUROMUTLIN DERIVATIVES AS ANTIMICROBIALS | SMITHKLINE BEECHAM PLC (GB) | 2004-09-01 | — | — | EP | disclosed |
| US-6468998-B1 | ANTAGONIZE SEROTONIN 2 RECEPTORS, SUPPRESS PLATELET AGGREGATION, IMPROVE PERIPHERAL CIRCULATION AND PROMOTE LACHRYMATION | MITSUBISHI PHARMA CORPORATION (JP) | 2002-10-22 | — | — | US | disclosed |
| US-6281226-B1 | Pleuromutilin derivatives as antimicrobials | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-08-28 | — | — | US | disclosed |
| EP-1125922-A1 | PYRROLIDINE COMPOUNDS AND MEDICINAL UTILIZATION THEREOF | Welfide Corporation (JP) | 2001-08-22 | — | — | EP | disclosed |